BPC-157 Certificate of Analysis QA Review Checklist

Which identity fields open a BPC-157 certificate of analysis?

Identity is the first gate, because a purity percentage is meaningless if the peak is the wrong peptide. Copy the product name, any synonym, the one-letter sequence, the residue count and the salt form before reading area percent. Published reports designate BPC 157 as a gastric pentadecapeptide, so the certificate should state fifteen residues, not a range (PMID:14554208; PMID:30915550). Count every letter in the sequence and write the count beside the string. If the certificate prints GEPPPGKPADDAGLV, count those fifteen letters and confirm the laboratory expected that string. Three-letter code, if present, must translate to the same string. State N-terminal and C-terminal status explicitly. A free acid and a C-terminal amide do not share a theoretical mass, so an unspecified terminus is an identity gap. Separate catalogue name, lot number, specification identifier and report identifier. A catalogue code can remain constant while the lot changes; a report identifier should change when the analytical file changes. A corrigendum in the experimental literature shows why version state matters: later documents can amend earlier ones, so the certificate should show whether it is original or revised (PMID:35126157). Record the testing laboratory, the analysis date, the reviewer sign-off and whether any accreditation claim is a scope sentence rather than a logo alone. Place salt form in the identity block. Acetate and trifluoroacetate both appear on synthetic peptide certificates and change gross mass and content calculations. If the page says only BPC-157, mark the salt form undeclared. Check product name, lot number and fill statement against the vial label and the packing list. A mismatch is a traceability failure before any purity number is accepted.

How should HPLC purity and related substances be read on the certificate?

Chromatographic purity is usually an area-normalised reversed-phase HPLC result, not a mass-balance assay. Record wavelength, column, gradient or isocratic statement, integration rule, result and the specification limit on the same page. A result without a limit, or a limit without a method identifier, is incomplete. Peptide bonds absorb strongly near 214 nm; aromatic side chains dominate near 280 nm. The pentadecapeptide literature names the analyte but does not supply a chromatographic monograph (PMID:29998800; PMID:32329684). The certificate must state the detection channel. The peak table outweighs the summary line. Record main-peak retention time, each related-substance relative retention time, each area percent, and whether areas sum to about 100 percent after stated exclusions. Label solvent fronts and sub-threshold peaks as exclusions. If table and summary disagree beyond rounding, ask for the processing method. Unidentified peaks need a code and a relative retention time. An unidentified peak above the reporting threshold is an open impurity entry. Synthesis can leave deletion sequences, especially near proline-rich stretches, plus truncation products. The certificate need not narrate every pathway, but it should show separation of the main peak from near-eluting impurities. Resolution, tailing and system suitability belong in the method block. A lone figure near 99 percent, with no chromatogram and no peak table, cannot be reconciled. Check run time, because a short acquisition can miss a late-eluting impurity. Do not add sub-threshold peaks back into purity. If no threshold is stated, record the ignore limit as unknown. Any attached chromatogram must show the same lot, sample name and time axis as the table. Instrument, column, date and operator in the footer should match the header.

Which mass-spectrometry results confirm the pentadecapeptide?

Area percent does not prove sequence. Identity confirmation should include observed mass, theoretical mass, monoisotopic or average definition, charge state or deconvolution method, and mass error. Calculate the theoretical mass from the printed sequence, including terminus status. If a mass appears without the sequence, mark identity unverified. Papers that call the material a stable gastric pentadecapeptide fix the name, not the mass of this lot (PMID:34267654; PMID:36200148). Record the instrument in plain language: electrospray ionisation, unit-resolution or high-resolution, or MALDI, as stated. High-resolution data should show error in parts per million or daltons, with the acceptance window beside the result. A missing window is not a pass. Multiply charged spectra should state how the neutral mass was obtained. Compare neutral mass with neutral mass, not with an m/z value from another charge state. A resolved isotope cluster is stronger than a single stick with no resolution statement. Where tandem data are supplied, look for a partial ion series covering distinctive residues, not only a precursor mass. Deletion peptides can lie close in mass to the parent. A proline deletion shifts mass by about one proline residue. Co-eluting deletions are clearer when the chromatogram and tandem data are read together. Confirm that mass data and the HPLC main peak share sample name and lot. Data from another lot do not confirm this vial. Published reports that use the same name, including nitric-oxide system reviews, do not assign fragment ions (PMID:23755725; PMID:35884767). The only QA question is whether measured mass, and any fragments, match the printed sequence within the stated error for this lot and date.

How are counter-ion, water and net peptide content reconciled?

HPLC area percent and net peptide content answer different questions. Area percent is the share of detected peptide-like signal in the main peak. Net peptide content is the share of weighed solid that is peptide rather than water, counter-ion, residual solvent or other non-peptide mass. Ranking Australian research lots by purity percent alone mis-ranks them when one solid is acetate and another is trifluoroacetate, or when water differs. Look for three linked rows: counter-ion identity and amount, water by a named method such as Karl Fischer titration, and net peptide content with its calculation basis. If amino-acid analysis is used, name the method. A net-content figure without a calculation is unsupported. State whether the result is free peptide, peptide as salt, or peptide corrected for water. Record that basis in the review notes so a later comparison does not treat unlike solids as equivalent. Preserve the basis beside the numeric result so certificates can be compared on the same definition of net peptide content. Residual trifluoroacetate needs its own row, because that counter-ion can remain after cleavage and purification. An acetate claim should rest on a counter-ion result, such as ion chromatography, not only on the word acetate in the title. Residual solvent rows should name the solvent, the method and the limit. A complies cell with no method is weaker than a number. Reconcile by mass balance. Peptide, counter-ion, water and residual solvent should be directionally consistent with gross mass. They need not sum to 100 percent, but a large unexplained gap is a query. Keep units consistent: mass percent, milligrams per vial and micromoles per vial must not be mixed. Label fill mass should match the fill mass in the calculation. Experimental reports on this pentadecapeptide do not define a commercial net-content convention (PMID:21030672; PMID:32445447).

What lot-traceability and data-integrity items close the review?

A tidy percentage can still fail traceability. Tie every result to one lot number written the same way on the header, the chromatogram sample name, the mass-file name, the vial label and the packing list. Extra characters or an undefined date-style code are mismatches. For multi-vial orders, check whether every vial is stated to come from one released lot. Read data integrity in an ALCOA-style way: attributable, legible, contemporaneous, original and accurate. Attributable means a named laboratory and a named reviewer, not an unsigned file. Legible means the peak table is readable and the chromatogram is not cropped so late peaks disappear. Contemporaneous means the analysis date is not later than the report date, and not much earlier without a retest note. Original means a controlled report identifier and a revision number if reissued. Accurate means peak-table arithmetic matches the purity statement within rounding, using the printed limit. The certificate records measurements for the named lot and the named method. It does not stand in for the chromatogram, the mass file or the content calculation that support those figures. A literature name for the peptide is not a lot-specific analytical result. File the checklist with the purchase line, the batch number and the tracked-dispatch reference so the analytical file can be retrieved. Cross-reference chromatogram, spectrum, moisture and counter-ion attachments. Missing attachments are open items, accepted only under a written waiver that names the unverified element. Red flags include a purity figure that contradicts the peak table, a lot number that changes between pages, a method name with no parameters, a chromatogram axis that does not match peak times, and a sign-off date before the analysis date. Any one prompts a supplier query before the lot is booked in. Cite the field and the page so the reply files against the same row.

BPC-157 certificate of analysis QA review checklist: how is the record kept in Australia?

An Australian laboratory keeps the review as a controlled procurement record. The file holds the completed checklist, the certificate, attachments, a vial-label transcription, the purchase-order line and the goods-receipt batch number. State the decision: accept, accept with waiver, or query. A decision without a date and a reviewer name is incomplete. Use limits printed on the certificate or written in the incoming-material procedure. Do not borrow limits from an unrelated peptide monograph. A research-lot specification is the supplier's stated specification for that material. It is not a limit set borrowed from a different peptide. Internal alert limits, such as an unidentified peak above a chosen area percent, belong in the procedure and are cited by identifier. They are laboratory policy recorded against the procedure identifier, not figures taken from another material's specification. Goods receipt can link the file to local Australian stock and a tracked-dispatch reference. Note that the parcel lot matched the certificate lot, and store the tracking reference beside the report identifier. The receipt note records that concordance only. Keep the supplier's research-material designation beside the chemical name in inventory so the documentation scope travels with the lot. If a revised certificate arrives, retain the old file, mark it superseded, and repeat the checklist rather than editing it in place. Corrigendum practice is the analogy: amendments stay visible, and the earlier text remains available (PMID:35126157). A retain-sample retest gets a new identifier and a cross-reference. The lot history can then be audited for what was claimed, checked and waived, and for which document was current at booking. That close is the point of a BPC-157 certificate of analysis QA review checklist.

Frequently asked questions

What should be checked before the purity percentage on a BPC-157 certificate?

Check the name, the fifteen-residue sequence, the terminus status, the salt form and the lot number against the vial label. A purity figure for an unspecified sequence, or for a lot number that does not match the label, cannot be interpreted. Published reports use the gastric pentadecapeptide designation, but that name alone does not confirm the vial (PMID:30915550). Record gaps before comparing area percent.

Why can two lots with the same HPLC purity not be equivalent?

Area percent describes the main peak relative to other detected peptide-like peaks. It does not describe water, counter-ion or residual solvent in the solid. An acetate solid and a trifluoroacetate solid can share a purity percentage and differ in net peptide content. Compare certificates only after the calculation basis, the water method and the counter-ion result are recorded. Do not infer content from the purity line.

Does a paper that names stable gastric pentadecapeptide BPC 157 replace lot identity testing?

No. That wording is a literature designation used across experimental reports (PMID:34267654; PMID:36200148). It does not report the mass error, the chromatogram or the counter-ion for a commercial research lot. Identity still requires the printed sequence, a measured mass within a stated window, and concordance between the certificate and the vial. A paper title is not a specification limit.

Which related-substance findings should pause acceptance?

Pause if an unidentified peak sits above the stated reporting threshold, if the peak table does not sum consistently with the purity line, or if resolution from a near-eluting peak is not shown. Deletion products can sit close to the main peak, particularly around proline-rich sequences, so a single summary percentage is not enough. Also pause if the chromatogram lot number differs from the certificate header. Query the supplier and file the reply.

What should the Australian batch file contain once the checklist is signed?

The batch file should hold the completed checklist, the certificate, the chromatogram and mass attachments, the counter-ion and water results, a transcription of the vial label, the purchase-order line and the goods-receipt batch number. The decision line should state accept, accept with waiver, or query, with the reviewer name and the date. A waiver should name the unverified field rather than leave a blank. The report identifier and the tracked-dispatch reference should sit on the same row as the lot number so the analytical file can be retrieved later. If any attachment is missing, the file should show that gap as open. A later reader should be able to see which specification limit was applied and which document identifier was current.

What if the certificate is revised after receipt?

Retain the original file, mark it superseded, and repeat the checklist against the revised report rather than editing the old review in place. A corrigendum in the BPC 157 literature illustrates the same discipline: amendments should stay visible (PMID:35126157). Cross-reference the new report identifier to the lot and to any retain-sample retest. Do not overwrite historical results. The booking decision should cite the document that was current on that date.

References

1. PMID:14554208 — Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth — J Orthop Res — 2003
2. PMID:21030672 — The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — J Appl Physiol (1985) — 2011
3. PMID:21548867 — Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract — Curr Pharm Des — 2011
4. PMID:23755725 — Stable gastric pentadecapeptide BPC 157-NO-system relation — Curr Pharm Des — 2014
5. PMID:29998800 — BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing — Curr Pharm Des — 2018
6. PMID:30915550 — Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — Cell Tissue Res — 2019
7. PMID:32329684 — Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy — Curr Pharm Des — 2020
8. PMID:32445447 — BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection — Curr Pharm Des — 2020
9. PMID:34267654 — Stable Gastric Pentadecapeptide BPC 157 and Wound Healing — Front Pharmacol — 2021
10. PMID:35126157 — Corrigendum: Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats — Front Pharmacol — 2021
11. PMID:35884767 — BPC 157, L-NAME, L-Arginine, NO-Relation, in the Suited Rat Ketamine Models Resembling "Negative-Like" Symptoms of Schizophrenia — Biomedicines — 2022
12. PMID:36200148 — Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation of Collateral Pathways — Curr Med Chem — 2023

Research use only

This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.